Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines

Anwer, Md. Khalid; Fatima, Farhat; Ahmed, Mohammed Muqtader; Aldawsari, Mohammed F.; Ali, Amer; Kalam, Mohd Abul; Alshamsan, Aws; Alkholief, Musaed; Malik, Abdul; AZ, Alanazi; Al-Shdefat, Ramadan

doi:10.1016/j.jsps.2022.03.019

Cited by 17 publications

(14 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These particles can encapsulate both hydrophilic and lipophilic drugs, improving their solubility. Early studies have indicated that the use of NSPs may revolutionize the treatment of many diseases and that they are more effective than current techniques for delivering drugs to treat breast cancer [ 23 , 24 , 25 ]. Cyclodextrins-based nanosponges (CDNSPs) are porous structures that resemble sponges that may be prepared using CD and diphenylcarbonate (DPC) as cross linker [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

Preparation and Evaluation of Diosmin-Loaded Diphenylcarbonate-Cross-Linked Cyclodextrin Nanosponges for Breast Cancer Therapy

et al. 2022

Self Cite

View full text Add to dashboard Cite

In the current study, diosmin (DSM)-loaded beta-cyclodextrin (β-CD)-based nanosponges (NSPs) using diphenylcarbonate (DPC) as a cross-linker were prepared. Four different DSM-loaded NSPs (D-NSP1-NSP4) were developed by varying the molar ratio of β-CD: DCP (1:15–1:6). Based on preliminary evaluations, NSPs (D-NSP3) were optimized for size (412 ± 6.1 nm), polydispersity index (PDI) (0.259), zeta potential (ZP) (−10.8 ± 4.3 mV), and drug loading (DL) (88.7 ± 8.5%), and were further evaluated by in vitro release, scanning electron microscopy (SEM), and in vitro antioxidant studies. The NSPs (D-NSP3) exhibited improved free radical scavenging activity (85.58% at 100 g/mL) compared to pure DSM. Dissolution efficiency (%DE) was enhanced to 71.50% (D-NSP3) from plain DSM (58.59%). The D-NSP3 formulation followed the Korsmeyer–Peppas kinetic model and had an n value of 0.529 indicating a non-Fickian and controlled release by diffusion and relaxation. The D-NSP3 showed cytotoxic activity against MCF-7 breast cancer, as evidenced by caspase 3, 9, and p53 activities. According to the findings, DSM-loaded NSPs might be a promising therapy option for breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and Evaluation of Diosmin-Loaded Diphenylcarbonate-Cross-Linked Cyclodextrin Nanosponges for Breast Cancer Therapy

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…One of the study topics that need further inquiry and inspection is this one (9). In light of this, we made the decision to conduct research to determine the effects of apremilast on the release of VEGF in human estrogen receptor-positive breast cancer cells that were identified in tumors in vivo (9). In the present work, we demonstrate that Apremilast was effective in preventing VEGF synthesis when it was produced in vitro.…”

Section: Introductionmentioning

confidence: 65%

“…But little is understood about the hormonal regulation of VEGF, particularly how apremilast affects VEGF levels in the extracellular environment. One of the study topics that need further inquiry and inspection is this one (9). In light of this, we made the decision to conduct research to determine the effects of apremilast on the release of VEGF in human estrogen receptor-positive breast cancer cells that were identified in tumors in vivo (9).…”

Section: Introductionmentioning

confidence: 99%

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

2023

JPTCP

View full text Add to dashboard Cite

It is widely accepted that vascular endothelial growth factor, often abbreviated as VEGF, is an important mediator in the process of tumor angiogenesis, which includes neovascularization in human breast cancer. Patients with either node-positive or node-negative breast cancer have a worse prognosis overall if there are high levels of VEGF in the tissue. It would seem logical to expect a poor prognosis given these circumstances. There is evidence that the partial estrogen receptor agonist apremilast may increase the quantity of VEGF mRNA that is generated in breast cancer cells, suggesting that hormones may regulate the amount of VEGF that is expressed. However, the findings of clinical studies show that apremilast increases average survival rates while reducing the incidence of metastases. These results seem to raise questions about apremilast's efficacy as an adjuvant treatment for estrogen-dependent breast cancer. In this study, we demonstrate for the first time that apremilast can lower extracellular VEGF levels in vivo using solid MCF-7 tumors in naked mice. Nothing like to this has ever been done. Following the injection of apremilast, the levels of extracellular VEGF seen in the cell culture conditions were dramatically decreased. The in vivo outcomes that were found were supported by these findings.

show abstract

“…After the in vivo evaluation of the nanosponge-based system, the results were consistent with those obtained with cisplatin [ 74 ]. In addition, to improve the bioavailability of Abemaciclib (an anticancer drug against breast cancer), ethylcellulose nanosponges were created with sustained-release behavior via an emulsion solvent diffusion technique [ 75 ]. Consequently, the nanosponges exhibited high stability and sustained release of the drug (~77.12 ± 2.54%) in 24 h, with efficient cytotoxic activity versus MCF-7 and MDA-MB-231 human breast cancerous cells [ 75 ].…”

Section: Drug Delivery and Cancer Therapymentioning

confidence: 99%

“…In addition, to improve the bioavailability of Abemaciclib (an anticancer drug against breast cancer), ethylcellulose nanosponges were created with sustained-release behavior via an emulsion solvent diffusion technique [ 75 ]. Consequently, the nanosponges exhibited high stability and sustained release of the drug (~77.12 ± 2.54%) in 24 h, with efficient cytotoxic activity versus MCF-7 and MDA-MB-231 human breast cancerous cells [ 75 ]. Spherical ethylcellulose nanosponges with sustained-release behavior were prepared via a quasi-emulsion solvent diffusion technique and could be deployed for the delivery of hesperetin with anti-carcinogenic, tumor necrosis, and antioxidant effects [ 76 ].…”

Section: Drug Delivery and Cancer Therapymentioning

confidence: 99%

Nanosponges for Drug Delivery and Cancer Therapy: Recent Advances

Iravani

Varma

2022

Nanomaterials

View full text Add to dashboard Cite

Nanosponges with three-dimensional (3D) porous structures, narrow size distribution, and high entrapment efficiency are widely engineered for cancer therapy and drug delivery purposes. They protect the molecular agents from degradation and help to improve the solubility of lipophilic therapeutic agents/drugs with targeted delivery options in addition to being magnetized to attain suitable magnetic features. Nanosponge-based delivery systems have been applied for cancer therapy with high specificity, biocompatibility, degradability, and prolonged release behavior. In this context, the drug loading within nanosponges is influenced by the crystallization degree. Notably, 3D printing technologies can be applied for the development of novel nanosponge-based systems for biomedical applications. The impacts of polymers, cross-linkers, type of drugs, temperature, loading and mechanism of drug release, fabrication methods, and substitution degree ought to be analytically evaluated. Eco-friendly techniques for the manufacturing of nanosponges still need to be uncovered in addition to the existing methods, such as solvent techniques, ultrasound-assisted preparation, melting strategies, and emulsion solvent diffusion methods. Herein, the recent advancements associated with the drug delivery and cancer therapy potential of nanosponges (chiefly, cyclodextrin-based, DNAzyme, and ethylcellulose nanosponges) are deliberated, focusing on the important challenges and future perspectives.

show abstract

Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines

Cited by 17 publications

References 50 publications

Preparation and Evaluation of Diosmin-Loaded Diphenylcarbonate-Cross-Linked Cyclodextrin Nanosponges for Breast Cancer Therapy

Preparation and Evaluation of Diosmin-Loaded Diphenylcarbonate-Cross-Linked Cyclodextrin Nanosponges for Breast Cancer Therapy

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

Nanosponges for Drug Delivery and Cancer Therapy: Recent Advances

Contact Info

Product

Resources

About